Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|October 2, 2002
- Pharmaceutical Technology-10-02-2002
- Volume 26
- Issue 10
Will CROs Find Opportunity in a Reinvigorated European R&D Sector? Outsourcing Outlook
Author(s)Jim Miller
The European Union is attempting to reform its current business environment in hopes of restoring its role in the lobal R&D sector.
Advertisement
Articles in this issue
almost 24 years ago
FDA Launches Major Review of CGMPsalmost 24 years ago
Understanding Pharmaceutical Flowsalmost 24 years ago
An Overview of the Validation Approach for Moist Heat Sterilization, Part IIalmost 24 years ago
Cyclodextrins as Sustained-Release CarriersAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Advertisement
Advertisement